OPTR, PWRM, FHN, MBTF, TECD, - CRWEPicks.com Stock News! Optimer Pharmaceuticals, Power3 Medical Products, First Horizon National Corp., MBT Financial Corp. and Tech Data Corporation
Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR)
A Food and Drug Administration advisory panel will evaluate data on the oral drug, fidaxomicin. The medicine would be Optimer’s first product to reach the market if the FDA gives its approval.
Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). In two Phase 3 trials for the treatment of CDI, fidaxomicin was equally effective in clinical cure when compared to vancomycin, the only FDA approved product for CDI.
Clostridium difficile is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Illness from the bacterium most commonly affects older adults in hospitals or trin long term care facilities and typically occurs after use of antibiotic medications.( Read More http://crwepicks.com/?p=14925 )
For more information about this company please visit http://www.optimerpharma.com
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.